Skip to main content
Journal cover image

361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER

Publication ,  Conference
Wu, C; Strickler, JH; Cercek, A; Siena, S; André, T; Ng, K; Van Cutsem, E; Paulson, AS; Hubbard, J; Coveler, A; Fountzilas, C; Kardosh, A ...
Published in: Annals of Oncology
September 2022

Duke Scholars

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2022

Volume

33

Start / End Page

S700 / S701

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, C., Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., … Bekaii-Saab, T. (2022). 361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. In Annals of Oncology (Vol. 33, pp. S700–S701). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.499
Wu, C., J. H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, et al. “361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER.” In Annals of Oncology, 33:S700–701. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.499.
Wu C, Strickler JH, Cercek A, Siena S, André T, Ng K, et al. 361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. In: Annals of Oncology. Elsevier BV; 2022. p. S700–1.
Wu, C., et al. “361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S700–01. Crossref, doi:10.1016/j.annonc.2022.07.499.
Wu C, Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Paulson AS, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez Fernandez ME, Hsu L-I, Stecher M, Zhao K, Bekaii-Saab T. 361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. Annals of Oncology. Elsevier BV; 2022. p. S700–S701.
Journal cover image

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2022

Volume

33

Start / End Page

S700 / S701

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis